AK101

BIOLOGICAL3 trials

Sponsors

Akeso

Conditions

Plaque PsoriasisPsoriasis Vulgaris

Phase 1

A Clinical Study of AK101 in Subjects With Moderate to Severe Plaque Psoriasis

CompletedNCT04172233

AkesoPlaque Psoriasis

Start: 2018-01-09End: 2019-10-31Updated: 2025-03-03

Phase 2

Clinical Study of AK101 in Subjects With Moderate to Severe Plaque Psoriasis

CompletedNCT04173637

AkesoPlaque Psoriasis

Start: 2019-12-19End: 2022-03-03Updated: 2025-02-28

Phase 3

A Phase 3 Study of Efficacy and Safety of AK101 in Subjects With Psoriasis

CompletedNCT05120297

AkesoPsoriasis Vulgaris

Start: 2021-11-29End: 2022-09-29Updated: 2023-03-02

Related Papers

Efficacy, Safety and Pharmacokinetics of IL-17 Monoclonal Antibody Injection (AK111) in Patients with Moderate-to-Severe Plaque Psoriasis: A Randomized, Double-Blinded, Placebo-Controlled Phase Ib Multidose Escalation Clinical Study

Dermatology and Therapy2022-12-243 citations